Article info

PDF

Original article
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Authors

  1. Correspondence to Maarten Arends, Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam 1100 DD, The Netherlands; m.arends{at}amc.uva.nl
View Full Text

Citation

Arends M, Biegstraaten M, Wanner C, et al
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

Publication history

  • Received 12 June 2017
  • Revised 7 January 2018
  • Accepted 12 January 2018
  • Published online 7 February 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.